Saint-Herblain (France), October 16, 2020 – Valneva SE (“Valneva” or “the Company”) a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its single-shot Phase 3 chikungunya vaccine candidate VLA1553. This new designation from the EMA complements the Fast Track designation received by the U.S. Food and Drug Administration (FDA) in December 20181.

Read more:
Valneva’s Chikungunya Vaccine Candidate Awarded EMA Prime Designation

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh